Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort

被引：165

作者：

Faiz, Sarah ^{[1
]}

Giovannelli, Jonathan ^{[1
,2
]}

Podevin, Celine ^{[2
]}

Jachiet, Marie ^{[3
,4
]}

Bouaziz, Jean-David ^{[3
,4
]}

Reguiai, Ziad ^{[5
]}

Nosbaum, Audrey ^{[6
,7
]}

Lasek, Audrey ^{[8
]}

le Bouedec, Marie-Christine Ferrier ^{[9
]}

Aurelie Du Thah ^{[10
]}

Raison-Peyron, Nadia ^{[10
]}

Tetart, Florence ^{[11
]}

Duval-Modeste, Anne-Benedicte ^{[11
]}

Misery, Laurent ^{[12
]}

Aubin, Francois ^{[13
]}

Dompmartin, Anne ^{[14
]}

Morice, Cecile ^{[14
]}

Droitcourt, Catherine ^{[15
]}

Soria, Angele ^{[16
,17
]}

Arnault, Jean-Philippe ^{[18
]}

Delaunay, Juliette ^{[19
]}

Mahe, Emmanuel ^{[20
]}

Richard, Marie-Aleth ^{[21
]}

Schoeffler, Amelie ^{[22
]}

Lacour, Jean-Philippe ^{[23
]}

Begon, Edouard ^{[24
]}

Walter-Lepage, Amelie ^{[25
]}

Dillies, Anne-Sophie ^{[26
]}

Rappelle-Duruy, Sandrine ^{[27
]}

Barete, Stephane ^{[28
]}

Bellon, Nathalia ^{[29
]}

Beneton, Nathalie ^{[30
]}

Valois, Aude ^{[31
]}

Barbarot, Sebastien ^{[32
]}

Senechal, Julien ^{[33
,34
]}

Staumont-Salle, Delphine ^{[1
,2
]}

机构：

[1] CHU Lille, Serv Dermatol, F-59000 Lille, France

[2] Univ Lille, INSERM U995, Lille Inflammat Res Int Ctr, F-59000 Lille, France

[3] Dermatol Dept, Paris, France

[4] Univ Paris Diderot Paris VII, St Louis Hosp, AP HP, Sorbonne Paris Cite, Paris, France

[5] Polyclin Courlancy, Serv Dermatol, Reims, France

[6] Univ Lyon, Lyon Sud Univ Hosp, Allergy & Clin Immunol Dept, Lyon, France

[7] Univ Claude Bernard Lyon 1, INSERM U1111, Int Ctr Infectiol Rese, Ecole Normale Super Lyon, Lyon, France

[8] Hosp St Vincent Paul, Grp Hop Inst Catholique Lille, Serv Dermatol, Lille, France

[9] Univ Clermont Ferrand, Dermatol Dept, Clermont Ferrand, France

[10] Univ Montpellier, Serv Dermatol, CHU Montpellier, PCCI,INSERM, Montpellier, France

[11] Rouen Univ Hosp, Dept Dermatol, Inserm U519, Rouen, France

[12] Univ Hosp Brest, Dept Dermatol, Brest, France

[13] Univ Franche Comte, Serv Dermatol, Ctr Hosp Reg Univ Besancon, Besancon, France

[14] Caen Univ Hosp Ctr, Dept Dermatol, Caen, France

[15] Univ Rennes, Ctr Hosp Univ Pontchaillou, Serv Dermatol, Rennes, France

[16] Hop Tenon, AP HP, Paris HUEP, Serv Dermatol & Allergol, Paris, France

[17] Sorbonne Univ Paris, Cimi Paris, INSERM U1135, Paris, France

[18] Amiens Univ Hosp, Dept Dermatol, Amiens, France

[19] CHU Angers, Serv Dermatol, Angers, France

[20] Hop Victor Dupouy Argenteuil, Dept Dermatol, Argenteuil, France

[21] Aix Marseille Univ, Timone Hosp, AP HM, EA 3279,CEReSS Hlth Serv Res & Qual Life Ctr,Derm, F-13385 Marseille, France

[22] Ctr Hosp Reg Metz Thionville, Serv Dermatol, Hop Bel Air, Metz, France

[23] CHU Nice, Serv Dermatol, Hop Archet 2, Nice, France

[24] Ctr Hosp Rene Dubos, Serv Dermatol, Pontoise, France

[25] CHU La Miletrie, Serv Dermatol, Poitiers, France

[26] Ctr Hosp St Quentin, Serv Dermatol, St Quentin en Yvelines, France

[27] Hop Joseph Imbert, Serv Dermatol, Ctr Hosp Arles, St Quentin en Yvelines, France

[28] Sorbonne Univ, Hop La Pitie Salpetriere, AP HP, Unite Fonct Dermatol, Paris, France

[29] Hop Necker Enfants Malad, AP HP, Serv Dermatol, Paris, France

[30] Ctr Hosp Le Mans, Serv Dermatol, Le Mans, France

[31] Hop Instruct Armees St Anne, Serv Dermatol, Toulon, France

[32] CHU Nantes, Serv Dermatol, Nantes, France

[33] CHU Bordeaux, Hop St Andre, Serv Dermatol, Ctr Reference Malad Rares Peau, Bordeaux, France

[34] Univ Bordeaux, INSERM Biotherapie Malad Genet Inflammatoires & C, Immunodermatol ATIP AVENIR, Bordeaux, France

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2019年 / 81卷 / 01期

关键词：

adults; atopic dermatitis; biotherapy; conjunctivitis; dupilumab; eosinophilia; PERSISTENT ASTHMA; PLACEBO;

D O I：

10.1016/j.jaad.2019.02.053

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Background: Dupilumab is the first biologic available to treat atopic dermatitis (AD). Its effectiveness and safety were demonstrated in clinical trials. Objective: We sought to assess the effectiveness and safety of dupilumab in adults with AD in a real-life French multicenter retrospective cohort. Methods: We included patients treated during March 2017-April 2018. Efficacy outcomes, including Scoring Atopic Dermatitis (SCORAD) and Eczema Area and Severity Index (EASI) scores, were collected at baseline and 3 months when available. Adverse events (AEs) were recorded at follow-up. Results: We included 241 patients. The median 6 interquartile range (IQR) follow-up time was 3.8 +/- 3.7 months. A >= 75% improvement in SCORAD was achieved in 27 of 163 (16.6%) patients, and a >= 75% improvement in EASI was achieved in 40 of 82 (48.8%) patients. The median SCORAD and EASI scores at 3 months were significantly lower than those at baseline (SCORAD +/- IQR, 25 +/- 21 vs 56 +/- 27.4, P < 10(-9) and EASI +/- IQR, 4.1 +/- 6.8 vs 17.9 +/- 15.4, P < 10(-9), respectively). Conjunctivitis was reported in 84 of 241 (38.2%) patients. The proportion with eosinophilia (<500 cells/mm(3)) during follow-up (57%) was higher than that at baseline (33.7%) (n = 172, P < 10(-6)). Dupilumab was stopped in 42 cases; 27 patients stopped because of AEs. Limitations: No control group, missing data. Conclusion: This real-life study demonstrated a similar dupilumab effectiveness as that seen in clinical trials, but it also revealed a higher frequency of conjunctivitis and eosinophilia.

引用

页码：143 / 151

页数：9

共 15 条

[1] Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis A Randomized Clinical Trial
Bachert, Claus
Mannent, Leda
Naclerio, Robert M.
Mullol, Joaquim
Ferguson, Berrylin J.
Gevaert, Philippe
Hellings, Peter
Jiao, Lixia
Wang, Lin
Evans, Robert R.
Pirozzi, Gianluca
Graham, Neil M.
Swanson, Brian
Hamilton, Jennifer D.
Radin, Allen
Gandhi, Namita A.
Stahl, Neil
Yancopoulos, George D.
Sutherland, E. Rand
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (05): : 469 - 479
[2] Epidemiology of atopic dermatitis in adults: Results from an international survey
Barbarot, S.
Auziere, S.
Gadkari, A.
Girolomoni, G.
Puig, L.
Simpson, E. L.
Margolis, D. J.
de Bruin-Weller, M.
Eckert, L.
[J]. ALLERGY, 2018, 73 (06) : 1284 - 1293
[3] Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Blauvelt, Andrew
de Bruin-Weller, Marjolein
Gooderham, Melinda
Cather, Jennifer C.
Weisman, Jamie
Pariser, David
Simpson, Eric L.
Papp, Kim A.
Hong, H. Chih-Ho
Rubel, Diana
Foley, Peter
Prens, Errol
Griffiths, Christopher E. M.
Etoh, Takafumi
Pinto, Pedro Herranz
Pujol, Ramon M.
Szepietowski, Jacek C.
Ettler, Karel
Kemeny, Lajos
Zhu, Xiaoping
Akinlade, Bolanle
Hultsch, Thomas
Mastey, Vera
Gadkari, Abhijit
Eckert, Laurent
Amin, Nikhil
Graham, Neil M. H.
Pirozzi, Gianluca
Stahl, Neil
Yancopoulos, George D.
Shumel, Brad
[J]. LANCET, 2017, 389 (10086) : 2287 - 2303
[4] Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE)
de Bruin-Weller, M.
Thaci, D.
Smith, C. H.
Reich, K.
Cork, M. J.
Radin, A.
Zhang, Q.
Akinlade, B.
Gadkari, A.
Eckert, L.
Hultsch, T.
Chen, Z.
Pirozzi, G.
Graham, N. M. H.
Shumel, B.
[J]. BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) : 1083 - 1101
[5] Methotrexate Versus Cyclosporine in Adults with Moderate-to-Severe Atopic Dermatitis: A Phase III Randomized Noninferiority Trial
Goujon, Catherine
Viguier, Manuelle
Staumont-Salle, Delphine
Bernier, Claire
Guillet, Gerard
Lahfa, Morad
Le Bouedec, Marie-Christine Ferrier
Cambazard, Frederic
Bottigioli, David
Grande, Sophie
Dahel, Karima
Berard, Frederic
Rabilloud, Muriel
Mercier, Catherine
Nicolas, Jean-Francois
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2018, 6 (02) : 562 - +
[6] Guidelines of care for atopic dermatitis
Hanifin, JM
Cooper, KD
Ho, VC
Kang, SW
Krafchik, BR
Margolis, DJ
Schachner, LA
Sidbury, R
Whitmore, SE
Sieck, CK
Van Voorhees, AS
[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : 391 - 404
[7] The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
Hanifin, JM
Thurston, M
Omoto, M
Cherill, R
Tofte, SJ
Graeber, M
[J]. EXPERIMENTAL DERMATOLOGY, 2001, 10 (01) : 11 - 18
[8] Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema
Lundberg, L
Johannesson, M
Silverdahl, M
Hermansson, C
Lindberg, M
[J]. BRITISH JOURNAL OF DERMATOLOGY, 1999, 141 (06) : 1067 - 1075
[9] Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis
Ou, Zuzhen
Chen, Chao
Chen, Aijun
Yang, Yao
Zhou, Weikang
[J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 54 : 303 - 310
[10] Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Rabe, Klaus F.
Nair, Parameswaran
Brusselle, Guy
Maspero, Jorge F.
Castro, Mario
Sher, Lawrence
Zhu, Hongjie
Hamilton, Jennifer D.
Swanson, Brian N.
Khan, Asif
Chao, Jingdong
Staudinger, Heribert
Pirozzi, Gianluca
Antoni, Christian
Amin, Nikhil
Ruddy, Marcella
Akinlade, Bolanle
Graham, Neil M. H.
Stahl, Neil
Yancopoulos, George D.
Teper, Ariel
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (26) : 2475 - 2485

← 1 2 →